OQ-04: Is vaginal estrogen safe for breast cancer survivors who take aromatase inhibitors?
Status: contested. Status as of . Version 1.0.
This page describes research, not your treatment. Talk to your own doctor about your situation, ideally with your cancer team.
What we can say today
Studies point in different directions. Large registry studies have not found higher mortality among survivors who used vaginal estrogen. One national study found a higher rate of cancer coming back in the group taking aromatase inhibitors. A 2026 review calls the effect on recurrence controversial.
Why it matters
Aromatase inhibitors lower estrogen in the body, and many survivors who take them notice vaginal dryness, pain and urinary symptoms. Vaginal estrogen is applied to local tissue. How much of it reaches the rest of the body is one of the questions the 2026 review examines. For survivors on a treatment designed to keep estrogen low, that is a genuine question.
For research, two outcomes need to be kept apart. Recurrence means the cancer comes back. Mortality means death from breast cancer. A study can find no signal for one and a signal for the other, and the sources below measured different things.
What is known
- Side A. A 2022 Danish national cohort in the Journal of the National Cancer Institute found no overall increase in recurrence or mortality with vaginal estrogen after early breast cancer. In the subgroup taking aromatase inhibitors, the relative risk of recurrence was 1.39 (95% CI 1.04 to 1.85). The study found no increase in mortality in that subgroup. [1]
- Side B. A 2024 registry cohort from Scotland and Wales in JAMA Oncology, with 49 237 women, found no evidence of higher breast cancer specific mortality with vaginal estrogen. The outcome was mortality, not recurrence, and the abstract reports no aromatase inhibitor subgroup. [2]
- A 2026 narrative review in Maturitas concludes that vaginal estrogen has not been associated with increased mortality, that its effect on recurrence remains controversial, and that no trials compare formulations head to head. [3]
Why it is still open
Both large studies are observational. People who receive vaginal estrogen may differ from those who do not in ways the data cannot fully capture. The Danish signal comes from a subgroup, which is smaller and less certain than the main result. The British registry looked at deaths, which take longer to show than recurrence, and did not report the aromatase inhibitor group separately in its abstract. So the two studies do not directly contradict each other. They answer different questions, and the particular question on this page sits in the gap between them.
None of the sources on this page reports a randomized trial in this group, and the 2026 review notes that formulations have not been compared head to head.
What would answer it
A large study of breast cancer survivors taking aromatase inhibitors, with vaginal estrogen use recorded in detail (product type, amount, duration), that reports recurrence and breast cancer deaths separately, with long follow-up. A randomized trial would give the clearest answer, but may be hard to run. A pooled analysis of national registries with a prespecified aromatase inhibitor subgroup would be a strong next step.
Sources
1. Cold, et al. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022. https://doi.org/10.1093/jnci/djac112 PMID 35854422. Verified on 2026-10-12. Role: side A.
2. McVicker, et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024. https://doi.org/10.1001/jamaoncol.2023.4508 PMID 37917089. Verified on 2026-10-12. Role: side B.
3. Mainar, et al. Safety of vaginal estrogen in breast cancer survivors: current evidence on systemic absorption and oncologic outcomes. Maturitas. 2026. https://doi.org/10.1016/j.maturitas.2026.108914 PMID 41864136. Verified on 2026-10-12. Role: context.
Related on MenoDerm
Status history
| Date | From | To | Reason | Source |
|---|---|---|---|---|
| (none) | contested | Page created, status set | (none) |
Cite this page
MenoDerm Open Question OQ-04, version 1.0, , /open-questions/is-vaginal-estrogen-safe-with-aromatase-inhibitors.
MenoDerm explains research. It does not give medical advice and is not a clinic. Talk to your own doctor about your situation. The status describes the research, not your situation.